New Study Finds That UCLA and Other Top Research Universities Have Done Little To Make New Drugs Accessible

Keerthi Vedantam

Keerthi Vedantam is a bioscience reporter at dot.LA. She cut her teeth covering everything from cloud computing to 5G in San Francisco and Seattle. Before she covered tech, Keerthi reported on tribal lands and congressional policy in Washington, D.C. Connect with her on Twitter, Clubhouse (@keerthivedantam) or Signal at 408-470-0776.

New Study Finds That UCLA and Other Top Research Universities Have Done Little To Make New Drugs Accessible

Despite gobbling up taxpayer dollars, UCLA and other top U.S. research universities are not doing enough to make drugs and medical devices financially accessible to people in low-income countries, a new report found.


Universities Allied for Essential Medicines, a student-run nonprofit focused on making costly medicines cheaper worldwide, used public data and a survey to rank 60 universities on their dedication to improve health disparities in low-income countries.

UCLA and 16 other top public universities that develop drug treatments got a D-minus rating for centering much of their research around private companies and failing to prioritize global health. The report also found the university failed to fund many projects that would help treat neglected diseases most common in low-income countries.

Avani Reddy, a neuroscience student at UCLA and one a member of UAEM, said the group compiled the report to ensure that her school and other universities were developing drugs at "sustainable prices and not obnoxious prices."

Georgetown and Harvard ranked highest with a B- while other UC system schools, including San Francisco and Davis, also got Ds, while Irvine got a F.

UCLA declined to respond to questions about the study, but said the university did not participate. UAEM ranked universities that did not respond lower than those that did.

"It should be that that research is accessible to people," said Devika Shenoy, a UCLA student and UAEM member studying human biology and society.

The 20-year-old student organization was born out of an effort by Yale University students to make an HIV/AIDS drug developed at the school and distributed by Bristol-Myers Squibb cheaper for low-income countries by allowing for the production of generics.

UCLA received $840 million in federal dollars for the 2019-2020 fiscal year, much of which went towards the medical and life sciences schools.

UAEM wants major federally funded research universities to focus on the issues big pharma companies find less profitable, like when Johns Hopkins surrendered a tuberculosis drug to a United Nations-supported organization to distribute the drug royalty-free. These schools, UAEM argues, should serve a larger public good in part because the public is paying for the research.

"Universities hold influence to leverage their significant contribution in biomedical research to advance global access to essential medicines and health technologies," the UAEM report said, pointing to the fact that one-third of new medicines originate in universities, according to a 2010 report.

UCLA has come under fire for drug access before. In 2016, the school sold a drug it developed to treat prostate cancer to Royalty Pharma. When a generic drug company in India tried to reproduce it, the school filed a patent claim, sparking protests. Ultimately, UCLA prevailed. But the incident highlights the pressure public-funded research universities are under to make their discoveries available and the competing demand from a market that relies on them.

Low and middle-income countries "may not have access to those resources to invest in R&D the way that schools like UCLA can in order to ensure that global public health needs are really being prioritized," Shenoy said.

COVID has brought these issues to the forefront. Oxford University originally developed its COVID-19 vaccine with the promise it would be open source so it could be distributed in low-income countries at a low cost or for free. Instead, it became the AstraZenca vaccine after the Gates Foundation brokered a deal between the two parties.

Meanwhile, only 0.1% of COVID-19 vaccines have made it to low-income countries. In 2020, organizations like Amnesty International warned that many in low-income countries would not have access to patented vaccines owned by wealthier countries. Vaccines specifically made with cheaper and accessible materials have just begun clinical trials, and pharma giant Pfizer will start testing a freeze-dried vaccine that can withstand higher temperatures this month.

Universities play a sizable role in the pharmaceutical pipeline, especially in preclinical development, according to Bill Bolding, a senior analyst at Provident Healthcare Partners. Venture firms and pharma companies rarely start investing in bioscience companies until there is proof of concept, much of which is created in university labs.

"Usually what you're seeing in the preclinical level is you're seeing like some kind of chemical reaction or proof of some kind of technology, in vitro," Bolding said.

https://twitter.com/KeerthiVedantam
keerthi@dot.la
LA Startups Supercharging Cars and Dating 🚗⚡💑

🔦 Spotlight

Happy Friday Los Angeles!

EVgo Inc., a leading Electric Vehicle (EV) charging company based in West Los Angeles, has seen substantial growth under CEO Badar Khan. The company now operates over 3,400 fast chargers across 1,000 sites nationwide, strategically placed in high-traffic urban and suburban areas to enhance convenience for EV users. EVgo’s model focuses on owning and managing its charging stations to ensure a seamless experience, reflecting its commitment to supporting the mass adoption of electric vehicles and facilitating the transition to cleaner transportation.

In a different electrifying market, Joe Feminella, inspired by his own successful dating journey, launched the dating app, First Round’s On Me in El Segundo with $5 million in funding. This app differentiates itself by requiring users to schedule a date within 24 hours of matching, and after a soft launch in select markets, it expanded nationwide in 2024. As the dating app market faces criticism over algorithmic practices and premium features, First Round’s On Me aims to offer a more genuine and immediate dating experience. Both EVgo and First Round’s On Me exemplify how companies in different industries are addressing their respective market challenges with innovative approaches to improve user experience and engagement.


🤝 Venture Deals

LA Companies

  • 3DEO, a startup that specializes in 3D printing small, high-volume metal parts, raised a $3.5M Strategic Investment Round from Mizuhio Bank. - learn more
  • Spotter, a startup that underwrites creators and offers AI tools, raised a $7.4M Funding Round. - learn more
  • Cashmere, a lead generation startup for wealth managers, raised a $3.6M Seed Round. Canapi Ventures led, and was joined by Benchstrength, Plug and Play, The House Fund, and Courtyard Ventures. - learn more

LA Venture Funds

  • Crosscut Ventures participated in an $8.9M Series A Extension for Nostra AI, a startup that helps e-commerce businesses improve their website performance by speeding up load times. - learn more
  • Fika Ventures, an eight-year-old Los Angeles venture capital firm, has raised a fourth fund in the amount of $160 million to invest in early-stage B2B startups. - learn more

      ✨ Featured Event ✨

      LA TECH CEO SUMMIT

      LA’s tech leadership is set to reunite after a long break! This two day summit will focus on building strong connections, sharing insights, and fortifying the local tech community.

      Learn More Here

      Register Here


      Download the dot.LA App

      🍵☕️Top 6 Coffee Alternatives for Enhanced Productivity

      In the fast-paced world of startups and venture capital in Los Angeles, maintaining peak productivity is essential for founders and investors alike. As the hustle intensifies, many are seeking alternatives to traditional coffee that not only provide a sustained energy boost but also support overall health and well-being. The following list highlights some of the top-rated coffee alternatives that can enhance focus and productivity while minimizing the adverse effects of caffeine. These options incorporate adaptogens, superfoods, and gut-friendly ingredients, making them ideal choices for those looking to optimize their performance without the afternoon crash.


      Matcha

      Image Source: Jade Leaf Matcha

      Matcha is a finely ground green tea that offers a moderate amount of caffeine, along with L-theanine, which promotes relaxation without drowsiness. This combination can enhance focus and concentration, making matcha a suitable alternative for those looking to boost productivity without the jitters of coffee.

      Popular Brands: ReNude Chaga Matcha (60 mg caffeine), Golde Pure Matcha (60 mg caffeine), Organic Ceremonial Matcha - Teahouse Edition (30 mg caffeine)


      Dandelion Root Coffee

      Image Source: Amazon

      Dandelion root coffee is a caffeine-free alternative that mimics the taste of coffee. It is known for its potential to support liver health and digestion, which can contribute to overall well-being and productivity. The drink can help avoid the acidity and jitters that often accompany regular coffee, making it a gentler option for those sensitive to caffeine.

      Popular Brands: Dandy Blend (0 mg caffeine), Teeccino Dandelion Dark Roast (0 mg caffeine)


      Adaptogenic Drinks

      Image Source: MUD\WTR Masala Chai

      Adaptogenic beverages, which include ingredients like ashwagandha, reishi, and maca, are designed to help the body adapt to stress and promote mental clarity. These drinks can provide a sustained energy boost without the crash, supporting productivity throughout the day. They are often made with superfoods and spices that enhance both physical and mental performance.

      Popular Brands: MUD\WTR Masala Chai (35 mg caffeine), Four Sigmatic Think Coffee (150 mg caffeine), ReNude Chagaccino (0 mg caffeine)


      Golden Milk (Turmeric Latte)

      Image Source: Golde

      Golden milk, made from turmeric, ginger, and milk (or a milk alternative), is a caffeine-free option that can improve mood and reduce inflammation. The calming properties of this drink can help maintain focus and clarity, making it a great addition to a productive morning routine.

      Popular Brands: Golde Turmeric Latte Blend (0 mg caffeine), Blume Turmeric Blend (0 mg caffeine), Four Sigmatic Golden Latte Mix (0 mg caffeine)



      Chicory Root Coffee

      Image Source: Teeccino

      Chicory root coffee is an excellent alternative that satisfies the desire for a warm beverage without caffeine. It is rich in inulin, a prebiotic fiber that aids in digestion and promotes gut health by supporting beneficial bacteria. Chicory coffee has a nutty, earthy flavor and can help control blood sugar levels, contributing to overall energy and productivity throughout the day.

      Popular Brands: Anthony’s Instant Chicory Root (0 mg caffeine), Teeccino Chicory Coffee Alternative (0 mg caffeine)


      Yerba Mate

      Image Source: Guayaki Yerba Mate

      Yerba mate is a traditional South American herbal tea made from the leaves of the Ilex paraguariensis plant. It contains about 40-80 mg of caffeine per serving, which is less than a standard cup of coffee but enough to provide a gentle energy boost. Yerba mate is rich in antioxidants, vitamins, and minerals, and users often report feeling energized without the jitters or crashes associated with coffee. It has a unique, slightly bitter flavor and can be enjoyed in various forms, including loose-leaf tea and pre-brewed options.

      Popular Brands: Guayaki Yerba Mate (40-150 mg caffeine)


      Download the dot.LA App

      LA’s Data Center Supply Crunch

      🔦 Spotlight

      Happy Friday Los Angeles!

      The Los Angeles data center market is experiencing a significant supply crunch, ranking 12th in growth among top markets since 2020 with only 265 megawatts of colocation inventory (data centers where businesses rent space to store their computing hardware and servers). Despite this, demand is surging, driven by AI, cloud, and hyperscaler needs, with AI accounting for 20% of new data center demand nationally. This scarcity is creating a highly competitive environment, with vacancy rates at a record low 3% and asking rents rising 13-37% year-over-year. For Los Angeles, this presents both challenges and opportunities in the big picture. The city's strategic position as a global entertainment hub and its connectivity to international markets through subsea cables make it an attractive location for data centers. However, the limited inventory and rising costs could potentially hinder growth and innovation in the tech sector. To maintain its competitive edge, Los Angeles will need to address these constraints through new developments, such as GI Partners' 16 MW addition at One Wilshire, and by focusing on high-connectivity, high-power capacity submarkets. The city's tech community should prepare for a landscape of increased competition for quality data center space, higher costs, and the need for innovative solutions to meet growing demand, particularly in AI and cloud services. While Los Angeles faces a challenging data center supply crunch, its strategic advantages and ongoing developments offer a promising path forward.


      🤝 Venture Deals

      LA Companies

      • Daisy, a one-year-old startup that designs and installs smart home and office technology systems, raised a $7M Series B co-led by Goldcrest and Bungalow, with previous investors Bullish and Burst Capital also stepping up. The company has raised a total of $13.3 million. - learn more

      LA Venture Funds


        ✨ Featured Event ✨

        LA TECH CEO SUMMIT

        LA’s tech leadership is set to reunite after a long break! This two day summit will focus on building strong connections, sharing insights, and fortifying the local tech community.

        Learn More Here

        Register Here


        Download the dot.LA App

        RELATEDEDITOR'S PICKS
        Trending